Form 4: LeonaBio CEO Litton Reports RSU Vesting, Tax-Related Stock Sale
Insider Transaction Report
LeonaBio, Inc.'s President and CEO, Mark James Litton, reported the vesting of 22,254 restricted stock units and a subsequent non-discretionary sale of 5,156 shares to cover tax obligations.
Summary
- Mark James Litton, President and CEO of LeonaBio, Inc. (LONA), reported changes in his beneficial ownership.
- On March 3, 2026, 22,254 Restricted Stock Units (RSUs) vested, converting into an equal number of common stock shares. These RSUs were granted on March 3, 2025, and vested 100% on their one-year anniversary.
- On March 4, 2026, Litton sold 5,156 shares of common stock at a weighted-average price of $5.37 per share.
- This sale was explicitly a "sell to cover" transaction to satisfy tax withholding and remittance obligations related to the RSU vesting, not a discretionary sale.
- Following these transactions, Litton directly owns 57,926 shares of common stock and indirectly owns 1,968 shares through three irrevocable trusts for his children.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. The RSU vesting is positive for the executive, but the 'sell to cover' is a non-discretionary tax-related sale, not indicative of a change in investment sentiment.
Positives
- The vesting of 22,254 Restricted Stock Units (RSUs) indicates a successful milestone for the executive's compensation plan.
Negatives
- A portion of the vested shares (5,156 shares) was sold, reducing the executive's direct ownership, although this was a non-discretionary sale for tax purposes.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that 'sell to cover' transactions are a common and expected practice for executives receiving equity compensation, particularly Restricted Stock Units (RSUs), across various industries. This transaction does not reflect a discretionary investment decision by the CEO but rather a standard mechanism to manage tax liabilities upon vesting.
Stakeholder Impact
- Shareholders: The sale of 5,156 shares by the CEO is a minor dilution event but is offset by the non-discretionary nature of the sale, which is unlikely to signal a lack of confidence.
- Employees: The RSU vesting demonstrates the company's commitment to executive compensation plans, which can be a positive signal for other employees with similar equity incentives.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Grant date of 22,254 Restricted Stock Units (RSUs) to Mark James Litton. |
| 09/17/2025 | Date of 10-for-1 reverse stock split, which adjusted the number of RSUs. |
| 03/03/2026 | Vesting date of 22,254 Restricted Stock Units (RSUs) and acquisition of common stock. |
| 03/04/2026 | Date of disposition of 5,156 common stock shares to cover tax obligations. |
| 03/05/2026 | Signature date of the Form 4 filing by Attorney-in-Fact. |
Recommendation
holdThe reported transactions are routine for executive equity compensation, involving the vesting of Restricted Stock Units and a non-discretionary 'sell to cover' for tax purposes. This does not indicate a change in the company's fundamentals or the executive's long-term view, thus a 'hold' recommendation is appropriate as there's no new information to warrant a change in investment thesis based solely on this filing.
Keywords
LeonaBio, LONA, Mark James Litton, Insider Trading, Form 4, Restricted Stock Units, RSU Vesting, Sell to Cover, Executive Compensation, Stock Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.